2C-I

Current official national law expressly controls 2C-I in United States; unauthorized possession, supply, or manufacture is prohibited.

The current federal Schedule 9 expressly lists 2C-I in the prohibition category.

Austria's current consolidated SV expressly lists 2C-I in Anhang V.2 and extends that row to the stated isomer, ester, ether, molecular-compound, salt and preparation clauses. Under SMG § 5, Suchtmittel may be handled only for medical, dental, veterinary or scientific purposes and under the Act; unauthorized acquisition, possession, production, transport, import/export, offering, transfer or supply is criminalized by SMG § 27, with personal-use and other fact-specific qualifications. Ordinary non-authorized conduct is prohibited, although not every act is unlawful. SV § 14 also bars prescribing preparations made from Anhang V substances (subject to cannabis-specific exceptions that do not apply to 2C-I), so no ordinary prescription route is established. The SGV 12.0 g figure is a criminal Grenzmenge calculated as pure active substance/free base, not a lawful possession allowance. The Austrian schedule gives the trivial name 2C-I; UNODC corroborates the chemical identity as 2,5-dimethoxy-4-iodophenethylamine. Analytical identity of a sample, purity, salt/base calculation in a particular case, authorization, import facts, and prosecutorial outcome are case-specific matters.

Belgium expressly added 2C-I (2,5-dimethoxy-4-iodophenethylamine) to the former psychotropic list in the Royal Decree published on 8 November 2004, effective 18 November 2004. That 1998 psychotropic decree was later repealed by the 2017 controlled-substances decree. The current AFMPS consolidation, valid from 29 March 2026 and corrected 16 July 2026, places 2C-X derivatives in Annex IVa under a generic structure; its 2C-X parent is 2-(2,5-dimethoxyphenyl)ethanamine and the listed R4 substituents include halogen, so the 4-iodo compound 2C-I is covered. Under current Article 7, importing, exporting, transporting, manufacturing, possessing, selling, supplying, delivering or acquiring scheduled products requires prior authorization, with authorization limited to scientific or medical purposes. The AFMPS schedule PDF is expressly a non-official consolidation: only Annexes and amendments published in the Moniteur belge have official legal value. Belgian law provides no ordinary recreational or personal-use exception.

Anvisa's PDF expressly lists 2C-I in Lista F2; the current Anvisa controlled-list page records periodic updates to the Portaria framework.

Current official national law expressly controls 2C-I in Canada; unauthorized possession, supply, or manufacture is prohibited.

The official Shenzhen Public Security Bureau current directory expressly places 2C-I in section III, the non-medical narcotic and psychotropic directory, as entry 241. Under Article 4 of the current national regulation, non-medical listed substances may be used only for legally compliant experimental research and may not be produced, dealt in, used, stored, or transported; this is a prohibited status, not ordinary prescription-only access. The 2025 medicinal schedules are separate from the non-medical directory. The classification applies to the exact listed 2C-I identity (CAS 69587-11-7); derivatives or analogues require separate identity analysis. The classification is limited to mainland China's national directories.

The current consolidated e-Sbírka text, effective from 25 June 2026, lists Ioddimethoxyfenethylamin, 2C-I and its chemical identity in Annex 4, List 4. Under the addictive-substance schedule, unauthorized handling is prohibited; this is not an absolute ban on every licensed scientific or very limited therapeutic activity.

The current 2026 regulation supersedes the 2020 instrument and identifies 2C-I precisely as List B item 97. List B substances may only be used for medical and scientific purposes, and the handling rule leaves no ordinary private-use or possession exception. The regulation's permissions are limited to specified medical/scientific actors, prescriptions or requisitions, agency-authorized activities and import/export certificates; its List A no. 2 treatment carve-outs and state-laboratory manufacture exception are narrow and do not make 2C-I generally lawful.

Riigi Teataja's schedule attachment places the exact parent compound in List I; distinct NBOMe derivatives are separately named.

Scheduled under the government decree on substances, preparations, and plants considered to be narcotic drugs.²⁹

The current ANSM consolidation places 2-CI in Annexe IV and attributes this listing to the 18 August 2004 amendment. This is an explicit named listing, not an inference from a generic analogue rule; it is also distinct from the separately listed 25I-NBOMe/2C-I-NBOMe entry. The ANSM PDF is an indicative compilation: it states that only the amended 22 February 1990 ministerial order and published ANSM director-general decisions are legally opposable, and that the Legifrance version does not include ANSM decisions since February 2022. The Ministry's PEPPS reference describes the general prohibition and offense-level penalties for classified narcotics. No prescription-medicine route is established for raw 2-CI; no authorized medicinal presentation is established.

Current official national law expressly controls 2C-I in Germany; unauthorized possession, supply, or manufacture is prohibited.

The exact parent compound is expressly listed in Greece's Table A at entry 43 of the official Law 3459/2006 Gazette. Under Law 4139/2013, Table A production, possession, transport, storage, procurement, processing, circulation and intermediation are State-exclusive, and disposal is limited to laboratories or hospitals for approved programs. An official Gazette amendment dated 11 June 2026 adds 2-MMC, NEP and 4-BMC to Table A and does not itself address 2C-I.

The exact structural provision is in Schedule 1 and the regulation's general prohibition applies.

The exact 2C-I identity is directly listed in First Schedule item 9A. Sections 7 and 13 make unauthorized possession/use and import/export/trade/other dealing/supply unlawful, while sections 7(c) and 19A state statutory maximums; these are maximum penalties, not automatic sentences, and licensing/statutory exceptions remain relevant. The current Ministry of Health import guidance requires the applicable permit/licence sequence, and the current Digital Personal Import Order places dangerous drugs in regulated First Schedule tariff categories under the Pharmacy Division. The latest official schedule amendment is dated 8 June 2025. The consolidated legal text states that it is current as of 17 June 2025, while the 2025 Gazette and current 2026 import guidance postdate that text.

The 11 January 2005 Ministry decree expressly names 2C-I as 2,5-dimetossi-4-iodofenetilamina and adds it to Table I; it was published on 7 March 2005 and entered into force the following day. A later official Table I schedule snapshot (2020) still prints both the common name 2C-I and the Italian chemical designation. Italy's current Normattiva page reports the consolidated D.P.R. 309/1990 view as vigente al 27/08/2026 and updated 06/08/2026. The Table I scheduling classification is prohibited, rather than prescription-only.

The original designated-substance classification and Pharmaceutical Affairs/PMD Act basis are superseded. MHLW's current list identifies 2C-I among substances formerly controlled as designated substances and records the 18 January 2008 reclassification; the current e-Gov Cabinet Order expressly lists the corresponding chemical identity and salts as a narcotic. Accordingly, the ordinary rule is prohibited under the Narcotics and Psychotropics Control Act, while the Act preserves licensed, research, disease-treatment/prescription, specified transfer, and permission-based treatment-import pathways. Those statutory pathways do not permit unlicensed recreational possession, sale or transfer.

The current structural rule covers substitution at the aromatic ring and therefore the exact iodinated parent.

The official publication also states the measure entered into force the day after publication.

The controlling rule is the specific Schedule 3 Part 7 amphetamine-analogue description rather than an unspecified catch-all. UNODC identifies 2C-I as 4-iodo-2,5-dimethoxyphenethylamine (IUPAC: 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine). The current New Zealand Act expressly defines Class C to include controlled drug analogues and defines an analogue by substantial structural similarity; Part 7's 1-amino-2-phenylethane rule reaches this identity. The Act's current named schedules separately list DOB, DMA, DMT and other substances, and Schedule 2 separately lists 25I-NBOMe (the N-(2-methoxybenzyl) derivative); neither should be conflated with parent 2C-I. Sections 6 and 7 retain criminal prohibitions on unauthorised controlled-drug import/export, production/manufacture, possession, consumption/use, and specified supply/sale. 2C-I is controlled as a Class C analogue rather than listed by exact name; it is not a prescription classification, and 25I-NBOMe's Class B status does not apply to parent 2C-I.

The exact parent compound is listed in Group I-P.

The exact parent compound is in Table II-A, subject to Portuguese statutory exceptions.

The current consolidated Läkemedelsverket schedule expressly identifies the exact parent compound 2C-I as 4-jodo-2,5-dimetoxifenetylamin and places it in Swedish list I. List I is defined by the schedule as substances normally without medical use. Under the current Narcotic Drugs Act, narcotics may be imported, exported, manufactured, offered for sale, transferred or possessed only for specified medical, scientific, specially important public-interest or permitted industrial purposes, and possession is limited to enumerated authorized categories; ordinary recreational possession, sale and supply are therefore prohibited.

The current ordinance is BetmVV-EDI (not the former DetMV name), and Verzeichnis d is the prohibited controlled-substance category. The current consolidated schedule expressly lists 2,5-Dimethoxy-4-iodo-phenethylamin (2C-I) in Annex 5 Verzeichnis d. BetmG Article 19(1)(d) makes unauthorized possession, custody, acquisition or other acquisition of narcotics punishable by up to three years' imprisonment or a fine. Unauthorized possession is prohibited, while licensed handling and BAG exceptions remain governed by the authorization framework.

Annex 1 of the official EGM/TUBİM 2013 national report lists substances brought within the scope of Law No. 2313 by Council of Ministers decisions and names 2C-I as 2,5-Dimethoxy-4-iodophenethylamine in the phenethylamine group under the 22 May 2013 Decision No. 2013/4827. Law No. 2313 remains one of Turkey's three fundamental drug-control statutes, and the TCK criminalizes manufacture, trade or supply and the purchase, possession or use of narcotic or stimulant substances.

Current official national law expressly controls 2C-I in United Kingdom; unauthorized possession, supply, or manufacture is prohibited.